Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

ith the FDA a possible Phase 3 registration trial evaluating first-line docetaxel with and without OGX-011 and the strategy of combining the first-line registration trial with one of the second-line clinical trials for product marketing approval for patients with CRPC. - Secure a development and commercialization partnership for OGX-011 in 2009. - Report data from our ongoing Phase 1 clinical trial evaluating OGX-427 as a monotherapy in patients with solid tumors; these data have been selected for presentation at the American Society of Clinical Oncology 2009 Annual Meeting in the second quarter. - Initiate an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 as a treatment in patients with bladder cancer, in the second quarter.

Financial Results

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of the OncoGenex Pharmaceuticals thereafter.

Research and development expenses for the fourth quarter and year ended December 31, 2008 were $4.2 million and $7.8 million, respectively, compared to $1.1 million and $4.1 million, respectively, in the corresponding periods of 2007. The increases in 2008 were primarily due to manufacturing costs incurred in the fourth quarter of 2008 associated with the development of our product candidate OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus.

General and administrative expenses for the fourth quarter and year ended December 31, 2008 were $1.0 million and $3.3 million, respectively, compared to $0.8 million and $3.5 million, respectively, in the corresponding periods of 2007. The increase for the fourth quarter of
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... proven cost-effective, Genomatica looks to develop demonstration plant ... Genomatica, a sustainable chemicals company, announced today that ... milestone toward the production of commercial grade 1,4-butanediol ... The company has demonstrated that it can ...
... Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, ... today announced that it will host a webcast on June 8, ... 6th at the 14th Congress of the European Hematology Association. ... www.micromet-inc.com . , , Forum: ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... vice president, corporate development and chief financial officer. Mr. ... biotechnology and pharmaceutical industry in corporate finance, corporate and business ... , Prior to joining Lexicon, Mr. Bansal was chief financial ...
Cached Biology Technology:Genomatica Produces Pure BDO From Natural Sugars 2Genomatica Produces Pure BDO From Natural Sugars 3Genomatica Produces Pure BDO From Natural Sugars 4Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 2Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 3Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 4Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer 2Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... USA Miranda, a small, icy moon of Uranus, ... bodies in the solar system. Despite its relatively small ... intense resurfacing that resulted in the formation of at ... regions called coronae. , These coronae are visible ... least 200 km across. Arden corona, the largest, has ...
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), ... in humans similar to that caused by Ebolavirus, has ... discovery has the potential to lead to novel targets ... The research, reported in a paper published today in ... scientists at the Texas Biomedical Research Institute and their ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Research milestone in CCHF virus could help identify new treatments 2
... 10, 2011 - Between conception and birth, the human ... coiling within the tiny abdomen. Within a given species, ... formationhowever, until now, it has not been clear why. ... biophysical manipulations, theory, and computation, researchers at Harvard have ...
... Woodland,s lab at the Trudeau Institute have now identified a ... to infected tissues and the ability of these cells to ... been cleared. The new data is featured on the cover ... "Defining the factors that regulate the generation of these ...
... Second graders who read aloud to a canine over ... dog days of summer, according to a pilot study published ... University. In the study, published in a whitepaper on ... aptitudes and attitudes toward reading were paired with dogsor peopleand ...
Cached Biology News:Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3Days spent reading to dogs during summer may help avoid decline of reading skills 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... REact Buffers are supplied as 10X concentrated ... vial of each of the REact buffers and ... Buffer SetConsists of four 1 ml vials of ... REact 2 Buffer four 1 ml vials of ...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
Biology Products: